| http://www.w3.org/ns/prov#value | - If you have questions or concerns about the FDA Oncologic Drugs Advisory Committee and its impending review of the safety of erythropoiesis stimulating agents, or ESAs, the class of drugs including Amgen's Aranesp and Epogen and Johnson & Johnson's Procrit, in cancer treatments, you should visit ESAFacts.org for continuing updates.
|
